Skip to main content
SpringerLink
Log in

Molecular typing—new targets and therapy options for upper GI carcinomas with a focus on adenocarcinomas of the esophagus, gastroesophageal junction, and stomach

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

The biomarker developments in adenocarcinomas of the esophagus, gastroesophageal junction, and stomach are currently very exciting. Clinical trial data for Claudin 18.2 and FGFR2b are promising and EMA approvals are expected. Routine testing includes PD-L1, HER2, and MSI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. access: 05.05.2023.. https://clinicaltrials.gov/..

  2. Athauda, A., et al. Claudin 18.2‑a FAST-moving target in gastric cancer?. Annals of oncology: official journal of the European Society for Medical Oncology (2021) 32(5), 584–586. https://doi.org/10.1016/j.annonc.2021.02.021

  3. Cao W, et al. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomark Res. 2022;10(1):38. https://doi.org/10.1186/s40364-022-00385-1.

    Article  MathSciNet  PubMed  PubMed Central  Google Scholar 

  4. Shitara, K., et al. Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW). J Clin Oncol 41, 2023 (suppl 16; abstr 4035); https://doi.org/10.1200/JCO.2023.41.16_suppl.4035

  5. Shitara, K., et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18. 2‑positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. The Lancet (2023).

  6. Pellino A, et al. Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas. JPM. 2021;11(11):1095.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Klempner SJ, et al. FGFR2-altered gastroesophageal adenocarcinomas (GEA) are a rare clinicopathologic entity with a. Distinct Genomic Landsc. 2019;.

  8. Wainberg, Z. A., et al. (2022). Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. The Lancet. Oncology, 23(11), 1430–1440. https://doi.org/10.1016/S1470-2045(22)00603‑9

  9. Gordon A, et al. Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments. OTT. 2022; 1183–96.

  10. Shitara K, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419–30.

    Article  CAS  PubMed  Google Scholar 

  11. Seo, S., et al. (2017). Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: Results of GASTric cancer HER2 reassessment study 3 (GASTHER3).

  12. Ruschoff, J., et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol (2023) 25(5):637–50.

  13. Yamaguchi K, et al. 1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study. Ann Oncol. 2020;31:S899–S900.

    Article  Google Scholar 

  14. Alsina M, et al. Current developments in gastric cancer: from molecular profiling to treatment strategy. Nat Rev Gastroenterol Hepatol. 2023;20:155–70. https://doi.org/10.1038/s41575-022-00703-w.

    Article  CAS  PubMed  Google Scholar 

  15. Schildhaus HU. Der prädiktive Wert der PD-L1-Diagnostik. Pathologe. 2018;39:498–519. https://doi.org/10.1007/s00292-018-0507-x.

    Article  PubMed  Google Scholar 

  16. European Commission approved Merck’s Keytruda (pembrolizumab) for patients with microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) tumors in five different types of cancer. News Release. Merck. April 29. 2022. https://www.merck.com/news/european-commission-approves-mercks-keytruda-pembrolizumab-for-patients-with-microsatellite-instability-high-msi-h-or-deficient-mismatch-repair-dmmr-tumors-in-five-different-types/. Accessed 12 Dec 2023.

  17. Stolze T, et al. Mismatch repair deficiency, chemotherapy and survival for resectable gastric cancer: an observational study from the German staR cohort and a meta-analysis. J Cancer Res Clin Oncol. 2023;149:1007–17. https://doi.org/10.1007/s00432-022-03953-y.

    Article  CAS  PubMed  Google Scholar 

  18. Puhr, H.C., et al. Immunotherapy for Esophageal Cancers: What Is Practice Changing in 2021? Cancers 2021, 13, 4632. https://doi.org/10.3390/cancers13184632

  19. Högner A, et al. Immunotherapy in Gastric Cancer. Curr Oncol. 2022;29:1559–74. https://doi.org/10.3390/curroncol29030131.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pathology and Molecular Pathology, Tyrolpath Obrist Brunhuber GmbH and St. Vinzenz Hospital, Zams, Austria

    Katja Schmitz

  2. St. Vinzenz Betriebs GmbH, Sanatoriumstraße 43, 6511, Zams, Austria

    Katja Schmitz

Authors
  1. Katja Schmitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katja Schmitz.

Ethics declarations

Conflict of interest

K. Schmitz received honoraria as advisor or speaker from: Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Diaceutics, Incyte, Janssen-Cilag, Eli Lilly, Merck, Merck Sharp and Dohme, Novartis Pharma, Pfizer, PharmaMar, Roche Pharma, Servier, Stemline, Takeda, Targos GmbH, and ZytoVision. K. S. received travel support from AstraZeneca, Merck, Novartis and PharmaMar.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schmitz, K. Molecular typing—new targets and therapy options for upper GI carcinomas with a focus on adenocarcinomas of the esophagus, gastroesophageal junction, and stomach. memo 17, 26–29 (2024). https://doi.org/10.1007/s12254-023-00950-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-023-00950-w

Keywords

Search

Navigation